Afatinib
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ genetics
Drug Resistance, Neoplasm
/ drug effects
ErbB Receptors
/ genetics
Esophageal Neoplasms
/ drug therapy
Esophagogastric Junction
/ pathology
Follow-Up Studies
Gene Amplification
Gene Expression Regulation, Neoplastic
Humans
Prognosis
Proto-Oncogene Proteins c-met
/ genetics
Receptor, ErbB-2
/ antagonists & inhibitors
Stomach Neoplasms
/ drug therapy
Trastuzumab
/ administration & dosage
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
25
05
2018
revised:
05
10
2018
accepted:
15
11
2018
pubmed:
23
11
2018
medline:
27
3
2020
entrez:
23
11
2018
Statut:
ppublish
Résumé
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with
Identifiants
pubmed: 30463996
pii: 2159-8290.CD-18-0598
doi: 10.1158/2159-8290.CD-18-0598
pmc: PMC6368868
mid: NIHMS1514186
doi:
Substances chimiques
Biomarkers, Tumor
0
Afatinib
41UD74L59M
EGFR protein, human
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
MET protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Banques de données
ClinicalTrials.gov
['NCT01522768']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-209Subventions
Organisme : NIH HHS
ID : U54 OD020355
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA150646
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204749
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA162361
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2018 American Association for Cancer Research.
Références
Ann Oncol. 2012 Oct;23(10):2656-2662
pubmed: 22689179
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
J Nucl Med. 2013 Jun;54(6):936-43
pubmed: 23578997
Cancer. 2013 Aug 15;119(16):3043-51
pubmed: 23775486
Sci Rep. 2013 Oct 21;3:2992
pubmed: 24141978
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Ann Oncol. 2018 Apr 1;29(4):1037-1048
pubmed: 29409051
Cancer Discov. 2018 Jan;8(1):49-58
pubmed: 29122777
Clin Proteomics. 2012 May 03;9(1):5
pubmed: 22554165
Cancer Discov. 2018 Jun;8(6):696-713
pubmed: 29449271
Ann Oncol. 2018 Apr 1;29(4):801-802
pubmed: 29462252
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Lancet Oncol. 2017 May;18(5):640-653
pubmed: 28343975
Clin Cancer Res. 2018 Mar 1;24(5):1082-1089
pubmed: 29208673
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
Clin Cancer Res. 2014 Sep 1;20(17):4559-73
pubmed: 24973425
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
BMC Cancer. 2011 Dec 07;11:509
pubmed: 22152101
Mol Cancer Ther. 2012 Mar;11(3):660-9
pubmed: 22238368
Clin Cancer Res. 2010 Mar 1;16(5):1509-19
pubmed: 20179222
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Cancer Cell. 2018 Apr 9;33(4):721-735.e8
pubmed: 29622466
Cancer Discov. 2018 Jan;8(1):37-48
pubmed: 28978556
PLoS One. 2014 Jul 01;9(7):e100586
pubmed: 24983965
Lancet Oncol. 2018 Oct;19(10):1372-1384
pubmed: 30217672
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Ann Thorac Surg. 2018 Feb;105(2):363-370
pubmed: 29223420
J Clin Invest. 2014 Dec;124(12):5145-58
pubmed: 25401468
Oncogene. 2008 Aug 7;27(34):4702-11
pubmed: 18408761
Gastric Cancer. 2016 Oct;19(4):1066-1079
pubmed: 26581548
Clin Cancer Res. 2015 Dec 15;21(24):5519-31
pubmed: 26296355
Oncologist. 2018 Sep;23(9):1092-1102
pubmed: 29700210
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Clin Oncol. 2014 Jul 1;32(19):2039-49
pubmed: 24868024
J Nucl Med. 2018 Jan;59(1):161-166
pubmed: 28637800
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Clin Oncol. 2017 Jul 10;35(20):2279-2287
pubmed: 28537764